Back to search

Boston University

A review of therapeutics targeting excitotoxicity in amyotrophic lateral sclerosis

Abstract

dc:description.abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects between 14,000 to 15,000 Americans. The upper and lower motor neurons degenerate, which eventually causes muscle paralysis, atrophy, and ultimately death from respiratory failure. It has a high treatment cost as well as a high toll on the patient and their families and friends. Currently, there are only two drugs approved by the FDA for the treatment of ALS: riluzole and edaravone. Research is constantly being conducted to understand and develop further treatment modalities, however, many drugs have failed to demonstrate significant improvement in phase III trials. One of the pathophysiology that these drugs, including riluzole, target is excitotoxicity of the motor neurons. This review will briefly expand upon the different trials that were conducted targeting the excitotoxicity pathway. Although they may have not been successful in prolonging survival in ALS patients, we can learn from these studies and build upon them.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2019

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Chang, Joshua Sua
Advisors dc:contributor.advisor
  • Gong, Haiyan
  • Offner, Gwynneth D.

Subjects

dc:subject × 3

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/36171

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chang, Joshua Sua. A review of therapeutics targeting excitotoxicity in amyotrophic lateral sclerosis. masters thesis, Boston University, 2019. https://hdl.handle.net/2144/36171